TIANJIN, China, Oct. 27, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, announced that the clinical trial results for its HT Supreme® Drug-Eluting Stent (DES) System has been published in Circulation.  The article described results from the PIONEER III trial where investigators demonstrated equivalence in safety and effectiveness between the […]

TIANJIN, China, July 6, 2020 /PRNewswire/ — SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug Administration and Japanese Pharmaceuticals […]

TIANJIN, China, July 23, 2019 /PRNewswire/ — In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial.  The PIONEER III trial is designed to assess the safety and effectiveness of the BuMA Supreme […]